La maladie de Parkinson au Canada (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « Neuroprotective agent »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Neuroprotective Agents (therapeutic use) < Neuroprotective agent < Neuropsychiatry  Facettes :

List of bibliographic references indexed by Neuroprotective agent

Number of relevant bibliographic references: 20.
Ident.Authors (with country if any)Title
000B86 (2014) Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
001956 (2011) Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada]Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects
002068 (2009) S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France]Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide
002119 (2009) Moonhee Lee [Canada] ; Claudia Schwab [Canada] ; SHENG YU [Canada] ; Edith Mcgeer [Canada] ; Patrick L. Mcgeer [Canada]Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide
002F07 (2003) J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis]Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
002F45 (2003) Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis]Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis
003084 (2002) Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France]Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture
003085 (2002) Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada]Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease
003092 (2002) C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada]Dopamine agonist monotherapy in Parkinson's disease
003096 (2002) Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada]Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity
003202 (2001) Doris J. Doudet [Canada]Monitoring Disease Progression in Parkinson's Disease
003334 (2001) Moussa B. H. Youdim [Israël] ; Edna Grünblatt [Israël] ; Yona Levites-Royak [Israël] ; Silvia Mandel [Israël]Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expression
003453 (2000) Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada]R -(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition
003588 (2000) M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS
003804 (1999) A. F. Miranda [Canada] ; M. A. Sutton [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] ; R. J. Boegman [Canada]Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus
003814 (1999) D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada]Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration
003A54 (1998) P. H. Yu [Canada] ; X. Zhang [Canada] ; D. M. Zuo [Canada] ; C. T. Lai [Canada] ; K. Tieu [Canada] ; B. A. Davis [Canada] ; A. A. Boulton [Canada]Aliphatic N-methylpropargylamines as potential neurorescue agents
003C39 (1997) A. F. Miranda [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada]Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid
003C54 (1997) C. Thiffault [Canada] ; L. Lamarre-Theroux [Canada] ; R. Quirion [Canada] ; J. Poirier [Canada]L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse
004159 (1994) Peter H. Yu [Canada]Pharmacological and clinical implications of MAO-B inhibitors

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Neuroprotective agent" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Neuroprotective agent" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective agent
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022